Thank You for reading

China and CRISPR gene therapy. We have just posted a new story

• The first data on a CRISPR cancer therapy trial in China is out, and CRISPR-Cas9-edited T cells appear to be feasible and safe. It sets the stage for the next significant advances in cancer treatment. Comments by leading experts Carl June, Waseem Qasim, Inge Marie Svane, and the study leaders Lu You and Tony Mok.

Related posts on gene therapy

• The Chinese study comes only two months after the first US CRISPR gene therapy led by Carl June. You can read our story on that here.
• And we have compiled a comprehensive list of all the gene-editing clinical studies currently registered in the US, China and Europe. Plus a companion article giving you the grand overview.

Did you miss?

• Last weeks fantastic overview of CRISPR Cas endonucleases currently in focus for therapeutic applications. Including some of the not so well-known family members as Cas3 and Cas12d.

Thank You for now - more great reads are on the way.

And if you have questions or suggestions, you can directly reach us at editor@crisprmedicinenews.com. We love hearing from readers!

(c; Rasmus

You can follow the blog on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up yourself here.